11:05 AM EDT, 09/16/2024 (MT Newswires) -- Voyager Therapeutics ( VYGR ) said Monday the joint steering committee with collaborator Neurocrine Biosciences ( NBIX ) selected a third development candidate in a gene therapy program to potentially treat an undisclosed neurological disease.

The move triggered a $3 million milestone payment to Voyager, expected to be received in Q4, the company said.

Voyager said it is eligible to receive additional development and commercialization milestone payments in the future, subject to further advancement of the program.

Price: 6.18, Change: -0.08, Percent Change: -1.20